Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer

Cancer

Volumn 107, Issue 4, 2006, Pages 738-745

  Ferrero, Jean Marc ^a   Chamorey, Emmanuel ^a   Oudard, Stephane ^b   Dides, Sabine ^c   Lesbats, Gerard ^d   Cavaglione, Gerard ^e   Nouyrigat, Pierre ^f   Foa, Cyril ^a   Kaphan, Regis ^g  

^a CENTRE ANTOINE LACASSAGNE   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c Centre Azureen de Cancerologie   (France)

^d Service d'Urologie   (France)

^e Clinique Saint Jean   (France)

^f Clinique de l'Esperance   (France)

^g Centre Hospitalier General   (France)

Author keywords

Capecitabine; Chemotherapy; Docetaxel; Hormone refractory; Prostate cancer

Indexed keywords

CAPECITABINE; DOCETAXEL; ESTRAMUSTINE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; LACRIMATION DISORDER; MALE; NAIL DISEASE; NAUSEA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROSTATE CANCER; SKIN TOXICITY; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, HORMONE-DEPENDENT; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK FACTORS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 33747188906     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22070     Document Type: Article

References (37)

1. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2004. CA Cancer J Clin. 2005;55:10-30.
2. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet. 2000;355:1491-1498.
3. Pienta K, Smith D. Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin. 2005;55:300-318.
4. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993;71:1098-1109.
5. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-1764.
6. Kantoff PW, Halabi S, Conaway M, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol. 1999;17:2506-2513.
7. Fizazi K, Sikes CR, Kim J, et al. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res. 2004;24:2897-2903.
8. Picus J, Schultz M, Cochrane J. A phase II trial of docetaxel in patients with hormone-refractory prostate cancer (HRPC): long term results. Proc Am Soc Clin Oncol. 1999;18:1206. Abstract.
9. Friedland D, Cohen J, Miller R Jr., et al. A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of Bcl-2. Semin Oncol. 1999;26(Suppl 17):19-23.
10. Berry W, Dakhil S, Gregurich MA, Asmar L. Phase II trial of single-agent weekly docetaxel in hormone-refractory, symptomatic, metastatic carcinoma of the prostate. Semin Oncol. 2001;28(Suppl 15):8-15.
11. Gravis G, Bladou F, Salem N, et al. Weekly administration of docetaxel for symptomatic metastatic hormone-refractory prostate carcinoma. Cancer. 2003;98:1627-1634.
12. Ferrero JM, Foa C, Thezenas S, et al. A weekly schedule of docetaxel for metastatic hormone-refractory prostate cancer. Oncology. 2004;66:281-287.
13. Kosty MP, Ferreira A, Bryntesen T. Weekly docetaxel and low-dose estramustine phosphate in hormone-refractory prostate cancer: a phase II study. Proc Am Soc Clin Oncol. 2001;20:2360. Abstract.
14. Tiersten AD, Nelsen C, Talbot S, et al. A phase II trial of docetaxel and estramustine in patients with refractory metastatic breast carcinoma. Cancer. 2003;97:537-544.
15. Sinibaldi VJ, Carducci MA, Moore-Cooper S, et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer. 2002;94:1457-1465.
16. Savarese DM, Halabi S, Hars V, et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B. J Clin Oncol. 2001;19:2509-2516.
17. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351:1513-1520.
18. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
19. Oudard S, Banu E, Beuzeboc P, et al. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer. J Clin Oncol. 2005;23:3343-3351.
20. Sawada N, Ishikawa T, Fukase Y, et al. Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol/taxotere in human cancer xenografts. Clin Cancer Res. 1998;4:1013-1019.
21. O'Shaughnessy J, Miles D, Vukelja S, et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002;20:2812-2823.
22. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999;17:3461-3467.
23. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
24. Aaronson NK, Ahmedzai S, Bergman B, et al. European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-376.
25. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5:299-314.
26. Haldar S, Chintipalli J, Croce CM. Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res. 1996;56:1253-1255.
27. Haldar S, Basu A, Croce CM. Bcl-2 is the guardian of microtubule integrity. Cancer Res. 1997;57:229-233.
28. Roth BJ, Yeap BY, Wilding GW, et al. Taxol in advanced, hormone refractory carcinoma of the prostate. A phase II trial of the Eastern Cooperative Oncology Group. Cancer. 1993;72:2457-2460.
29. Berry WR, Hathorn JW, Dakhil SR, et al. Phase II randomized trial of weekly paclitaxel with or without estramustine phosphate in progressive, metastatic, hormone-refractory prostate cancer. Clin Prostate Cancer. 2004;3:104-111.
30. Trivedi C, Redman B, Flaherty LE, et al. Weekly 1-hour infusion paclitaxel: clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer. 2000;89:431-436.
31. Eymard JC, Joly F, Priou F, et al. Phase II randomized trial of docetaxel plus estramustine (DE) versus docetaxel (D) in patients (pts) with hormone-refractory prostate cancer (HRPC): a final report. Proc Am Soc Clin Oncol. 2004;23:4603. Abstract.
32. Vaughn DJ, Brown AW Jr., Harker WG, et al. Multicenter phase II study of estramustine phosphate plus weekly paclitaxel in patients with androgen-independent prostate carcinoma. Cancer. 2004;100:746-750.
33. Hudes GR, Manola J, Conroy J, et al. Phase II study of weekly paclitaxel (P) by 1-hour infusion plus reduced-dose oral estramustine (EMP) in metastatic hormone-refractory prostate carcinoma (HRPC): a trial of the Eastern Cooperative Oncology Group. Proc Am Soc Clin Oncol. 2001;20:697. Abstract.
34. Hainsworth JD, Burris HA 3rd, Erland JB, et al. Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer. J Clin Oncol. 1998;16:2164-2168.
35. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol. 2004;22:2532-2539.
36. Beer TM, Eilers KM, Garzotto M, et al. Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J Clin Oncol. 2003;21:123-128.
37. Beer TM, Ryan CW, Venner PM, et al. Interim results from ASCENT: a double-blinded randomized study of DN-101 (high-dose calcitriol) plus docetaxel vs. placebo plus docetaxel in androgen-independent prostate cancer (AIPC). Proc Am Soc Clin Oncol. 2005;24:4516. Abstract.